




Tazarotene

Revised: May 1, 2019.

CASRN: 118292-40-3



Drug Levels and Effects

Summary of Use during Lactation

Topical tazarotene has not been studied during breastfeeding. Some experts feel it should not be used on greater than 20% of the body surface area while nursing because of possible absorption.[1] If tazarotene is used, ensure that the infant's skin does not come into direct contact with the areas of maternal skin that have been treated and the infant does not ingest the product from the mother's skin.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Psoriasis) [Adalimumab](#), [Etanercept](#), [Infliximab](#), [Phototherapy](#), [Tretinoin](#)

References

1. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II Lactation. *J Am Acad Dermatol.* 2014;70:417.e1-417.e10. PubMed PMID: 24528912.

Substance Identification

Substance Name

Tazarotene

CAS Registry Number

118292-40-3

Drug Class

Breast Feeding

Lactation

Dermatologic Agents

Keratolytic Agents